Selective Serotonin Reuptake Inhibitor and Substance P Antagonist Enhancement of Natural Killer Cell Innate Immunity in Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome

Biological Psychiatry

Volumn 63, Issue 9, 2008, Pages 899-905

  Evans, Dwight L ^a   Lynch, Kevin G ^a   Benton, Tami ^a   Dubé, Benoit ^a   Gettes, David R ^a   Tustin, Nancy B ^a   Lai, Jian Ping ^a   Metzger, David ^a   Douglas, Steven D ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Depression; innate immunity; natural killer cells; SSRI; substance P antagonists

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; CITALOPRAM; GLUCOCORTICOID; MIFEPRISTONE; NEUROKININ; SEROTONIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; BIPHENYL COMPOUNDS; CITALOPRAM; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; FEMALE; GLUCOCORTICOIDS; HIV SEROPOSITIVITY; HORMONE ANTAGONISTS; HUMANS; IMMUNITY, NATURAL; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MIDDLE AGED; MIFEPRISTONE; PERSONALITY INVENTORY; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE P; T-LYMPHOCYTES, CYTOTOXIC; VIRAL LOAD;

EID: 41449101409     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2007.08.012     Document Type: Article

References (88)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol 47 (1989) 187-376
2. Fauci A.S., Mavilio D., Kottilil S., Fauci A.S., Mavilio D., and Kottilil S. NK cells in HIV infection: Paradigm for protection or targets for ambush. Nat Rev Immunol 5 (2005) 835-843
3. Bandyopadhyay S., Ziegner U., Campbell D.E., Miller D.S., Hoxie J.A., and Starr S.E. Natural killer cell-mediated lysis of T cell lines chronically infected with HIV-1. Clin Exp Immunol 79 (1990) 430-435
4. Fortis C., Biswas P., Soldini L., Veglia F., Careddu A.M., Delfanti F., et al. Dual role of TNF-alpha in NK/LAK cell-mediated lysis of chronically HIV-infected U1 cells. Concomitant enhancement of HIV expression and sensitization of cell-mediated lysis. Eur J Immunol 29 (1999) 3654-3662
5. Oliva A., Kinter A.L., Vaccarezza M., Rubbert A., Catanzaro A., Moir S., et al. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest 102 (1998) 223-231
6. Douglas S.D., Durako S.J., Tustin N.B., Houser J., Muenz L., Starr S.E., et al. Natural killer cell enumeration and function in HIV-infected and high-risk uninfected adolescents. AIDS Res Hum Retroviruses 17 (2001) 543-552
7. Azzoni L., Papasavvas E., Chehimi J., Kostman J.R., Mounzer K., Ondercin J., et al. Sustained impairment of IFN-gamma secretion in suppressed HIV-infected patients despite mature NK cell recovery: Evidence for a defective reconstitution of innate immunity. J Immunol 168 (2002) 5764-5770
8. Fortis C., Tasca S., Capiluppi B., and Tambussi G. Natural killer cell function in HIV-1 infected patients. J Biol Regul Homeost Agents 16 (2002) 30-32
9. Weber K., Meyer D., Grosse V., Stoll M., Schmidt R.E., and Heiken H. Reconstitution of NK cell activity in HIV-1 infected individuals receiving antiretroviral therapy. Immunobiology 202 (2000) 172-178
10. Evans D.L., Charney D.S., Lewis L., Golden R.N., Gorman J.M., Krishnan K.R., et al. Mood disorders in the medically ill: Scientific review and recommendations. Biol Psychiatry 58 (2005) 175-189
11. Burack J.H., Barrett D.C., Stall R.D., Chesney M.A., Ekstrand M.L., and Coates T.J. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men [see comment]. JAMA 270 (1993) 2568-2573
12. Evans D.L., Ten Have T.R., Douglas S.D., Gettes D.R., Morrison M., Chiappini M.S., et al. Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry 159 (2002) 1752-1759
13. Ickovics J.R., Hamburger M.E., Vlahov D., Schoenbaum E.E., Schuman P., Boland R.J., et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: Longitudinal analysis from the HIV Epidemiology Research Study. JAMA 285 (2001) 1466-1474
14. Patterson T.L., Shaw W.S., Semple S.J., Cherner M., Nannis E., McCutchan J.A., et al. Relationships of psychosocial factors to HIV disease progression. Ann Behav Med 18 (1996) 30-39
15. Lyketsos C.G., Hoover D.R., Guccione M., Senterfitt W., Dew M.A., Wesch J., et al. Depressive symptoms as predictors of medical outcomes in HIV infection. Multicenter AIDS Cohort Study [see comment]. JAMA 270 (1993) 2563-2567
16. Lyketsos C.G., Hoover D.R., Guccione M., Dew M.A., Wesch J.E., Bing E.G., and Treisman G.J. Changes in depressive symptoms as AIDS develops. The Multicenter AIDS Cohort Study. Am J Psychiatry 153 (1996) 1430-1437
17. Mayne T.J., Vittinghoff E., Chesney M.A., Barrett D.C., and Coates T.J. Depressive affect and survival among gay and bisexual men infected with HIV. Arch Intern Med 156 (1996) 2233-2238
18. Page-Shafer K., Delorenze G.N., Satariano W.A., and Winkelstein Jr. W. Comorbidity and survival in HIV-infected men in the San Francisco Men's Health Survey. Ann Epidemiol 6 (1996) 420-430
19. Evans D.L., Mason D.K., Bauer R., Leserman J., and Petitto J. Neuropsychiatric manifestations of HIV-1 infection and AIDS. In: Charney D., Coyle J., Davis K., and Nemeroff C. (Eds). Psychopharmacology: The Fifth Generation of Progress (2002), Raven Press, New York 1281-1899
20. Irwin M., Daniels M., Bloom E.T., Smith T.L., and Weiner H. Life events, depressive symptoms and immune function. Am J Psychiatry 144 (1987) 437-441
21. Stein M., Miller A.H., and Trestman R.L. Depression, the immune system, and health and illness. Findings in search of meaning. Arch Gen Psychiatry 48 (1991) 171-177
22. Herbert T.B., and Cohen S. Depression and immunity: A meta-analytic review. Psychol Bull 113 (1993) 472-486
23. Reichlin S. Neuroendocrine-immune interactions. N Engl J Med 329 (1993) 1246-1253
24. Evans D.L., Folds J.D., Petitto J.M., Golden R.N., Pedersen C.A., Corrigan M., et al. Circulating natural killer cell phenotypes in men and women with major depression. Relation to cytotoxic activity and severity of depression. Arch Gen Psychiatry 49 (1992) 388-395
25. Kemeny M.E., and Dean L. Effects of AIDS-related bereavement on HIV progression among New York City gay men. AIDS Educ Prev 7 suppl 5 (1995) 36-47
26. Evans D.L., Leserman J., Perkins D.O., Stern R.A., Murphy C., Tamul K., et al. Stress-associated reductions of cytotoxic T lymphocytes and natural killer cells in asymptomatic HIV infection. Am J Psychiatry 152 (1995) 543-550
27. Leserman J., Petitto J.M., Perkins D.O., Folds J.D., Golden R.N., and Evans D.L. Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus-infected men. A 2-year follow-up study. Arch Gen Psychiatry 54 (1997) 279-285
28. Irwin M., Lacher U., and Caldwell C. Depression and reduced natural killer cytotoxicity: A longitudinal study of depressed patients and control subjects. Psychol Med 22 (1992) 1045-1050
29. Frank M.G., Hendricks S.E., Johnson D.R., Wieseler J.L., and Burke W.J. Antidepressants augment natural killer cell activity: In vivo and in vitro. Neuropsychobiology 39 (1999) 18-24
30. Schleifer S.J., Keller S.E., and Bartlett J.A. Depression and immunity: Clinical factors and therapeutic course. Psychiatry Res 85 (1999) 63-69
31. Cruess D.G., Douglas S.D., Petitto J.M., Have T.T., Gettes D., Dube B., et al. Association of resolution of major depression with increased natural killer cell activity among HIV-seropositive women. Am J Psychiatry 162 (2005) 2125-2130
32. Hellstrand K., and Hermodsson S. Serotonergic 5-HT1A receptors regulate a cell contact-mediated interaction between natural killer cells and monocytes. Scand J Immunol 37 (1993) 7-18
33. Hellstrand K., and Hermodsson S. Role of serotonin in the regulation of human natural killer cell cytotoxicity. J Immunol 139 (1987) 869-875
34. Betten A., Dahlgren C., Hermodsson S., and Hellstrand K. Serotonin protects NK cells against oxidatively induced functional inhibition and apoptosis. J Leukoc Biol 70 (2001) 65-72
35. Betten A., Dahlgren C., Mellqvist U.H., Hermodsson S., and Hellstrand K. Oxygen radical-induced natural killer cell dysfunction: Role of myeloperoxidase and regulation by serotonin. J Leukoc Biol 75 (2004) 1111-1115
36. Faraj B.A., Olkowski Z.L., and Jackson R.T. Expression of a high-affinity serotonin transporter in human lymphocytes. Int J Immunopharmacol 16 (1994) 561-567
37. Gordon J., and Barnes N.M. Lymphocytes transport serotonin and dopamine: Agony or ecstasy? [see comment]. Trends Immunol 24 (2003) 438-443
38. O'Connell P.J., Wang X., Leon-Ponte M., Griffiths C., Pingle S.C., and Ahern G.P. A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cells. Blood 107 (2006) 1010-1017
39. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors [see comment]. Science 281 (1998) 1640-1645
40. Stout S.C., Owens M.J., and Nemeroff C.B. Neurokinin(1) receptor antagonists as potential antidepressants. Annu Rev Pharmacol Toxicol 41 (2001) 877-906
41. Keller M., Montgomery S., Ball W., Morrison M., Snavely D., Liu G., et al. Lack of efficacy of the substance P (neurokinin 1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 59 (2006) 216-223
42. Kramer M.S., Winokur A., Kelsey J., Preskorn S.H., Rothschild A.J., Snavely D., et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 29 (2004) 385-392
43. Geracioti Jr. T.D., Carpenter L.L., Owens M.J., Baker D.G., Ekhator N.N., Horn P.S., et al. Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry 163 (2006) 637-643
44. Fehder W.P., Sachs J., Uvaydova M., and Douglas S.D. Substance P as an immune modulator of anxiety. Neuroimmunomodulation 4 (1997) 42-48
45. Michaels L.A., Ohene-Frempong K., Zhao H., and Douglas S.D. Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis. Blood 92 (1998) 3148-3151
46. Douglas S.D., Ho W.Z., Gettes D.R., Cnaan A., Zhao H., Leserman J., et al. Elevated substance P levels in HIV-infected men. AIDS 15 (2001) 2043-2045
47. Ho W.Z., and Douglas S.D. Substance P and neurokinin-1 receptor modulation of HIV. J Neuroimmunol 157 (2004) 48-55
48. Callewaert D.M., Moudgil V.K., Radcliff G., and Waite R. Hormone specific regulation of natural killer cells by cortisol. Direct inactivation of the cytotoxic function of cloned human NK cells without an effect on cellular proliferation. FEBS Lett 285 (1991) 108-110
49. Nair M.P., and Schwartz S.A. Synergistic effect of cortisol and HIV-1 envelope peptide on the NK activities of normal lymphocytes. Brain Behav Immun 9 (1995) 20-30
50. Nair M.P.N., Mahajan S., Hou J., Sweet A.M., and Schwartz S.A. The stress hormone, cortisol, synergizes with HIV-1 gp-120 to induce apoptosis of normal human peripheral blood mononuclear cells. Cell Mol Biol (Noisy-le-grand) 46 (2000) 1227-1238
51. Refaeli Y., Levy D.N., and Weiner D.B. The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product. Proc Natl Acad Sci U S A 92 (1995) 3621-3625
52. Schafer E.A., Venkatachari N.J., and Ayyavoo V. Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): Targeting Vpr and its cellular partner, the glucocorticoid receptor (GR). Antiviral Res 72 (2006) 224-232
53. Perkins D.O., Stern R.A., Golden R.N., Murphy C., Naftolowitz D., and Evans D.L. Mood disorders in HIV infection: Prevalence and risk factors in a nonepicenter of the AIDS epidemic. Am J Psychiatry 151 (1994) 233-236
54. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6 (1967) 278-296
55. Petitto J.M., Folds J.D., Ozer H., Quade D., and Evans D.L. Abnormal diurnal variation in circulating natural killer cell phenotypes and cytotoxic activity in major depression. Am J Psychiatry 149 (1992) 694-696
56. Douglas S.D., Rudy B., Muenz L., Moscicki A.B., Wilson C.M., Holland C., et al. Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescents. Adolescent Medicine HIV/AIDS Research Network. AIDS 13 (1999) 1629-1635
57. Gutierrez M., and Abramowitz W. Steady-state pharmacokinetics of citalopram in young and elderly subjects. Pharmacotherapy 20 (2000) 1441-1447
58. Bareggi S.R., Bianchi L., Cavallaro R., Gervasoni M., Siliprandi F., and Bellodi L. Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results. CNS Drugs 18 (2004) 329-335
59. Heikinheimo O., Kontula K., Croxatto H., Spitz I., Luukkainen T., and Lahteenmaki P. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. J Steroid Biochem 26 (1987) 279-284
60. Lahteenmaki P., Heikinheimo O., Croxatto H., Spitz I., Shoupe D., Birgerson L., and Luukkainen T. Pharmacokinetics and metabolism of RU 486. J Steroid Biochem 27 (1987) 859-863
61. Bryant J., Day R., Whiteside T.L., and Herberman R.B. Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Immunol Methods 146 (1992) 91-103
62. Friberg D.D., Bryant J.L., and Whiteside T.L. Measurements of natural killer (NK) activity and NK-cell qualifications. Methods 9 (1996) 316-326
63. Pollock R.E., Zimmerman S.O., Fuchshuber P., and Lotzova E. Lytic units reconsidered: Pitfalls in calculation and usage. J Clin Lab Anal 4 (1990) 274-282
64. Sephton S.E., Kraemer H.C., Neri E., Stites D.P., Weissbecker I., and Spiegel D. Improving methods of assessing natural killer cell cytotoxicity. Int J Methods Psychiatr Res 15 (2006) 12-21
65. Delgado P.L., Price L.H., Miller H.L., Salomon R.M., Aghajanian G.K., Heninger G.R., and Charney D.S. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 51 (1994) 865-874
66. Bymaster F.P., Dreshfield-Ahmad L.J., Threlkeld P.G., Shaw J.L., Thompson L., Nelson D.L., et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25 (2001) 871-880
67. Nemeroff C.B. New directions in the development of antidepressants: The interface of neurobiology and psychiatry. Hum Psychopharmacol 17 suppl 1 (2002) S13-S16
68. Mizruchin A., Gold I., Krasnov I., Livshitz G., Shahin R., and Kook A.I. Comparison of the effects of dopaminergic and serotonergic activity in the CNS on the activity of the immune system. J Neuroimmunol 101 (1999) 201-204
69. Dustin M.L., and Colman D.R. Neural and immunological synaptic relations. Science 298 (2002) 785-789
70. Jackson J.C., Walker R.F., Brooks W.H., and Roszman T.L. Specific uptake of serotonin by murine macrophages. Life Sci 42 (1988) 1641-1650
71. Finocchiaro L.M., Arzt E.S., Fernandez-Castelo S., Criscuolo M., Finkielman S., and Nahmod V.E. Serotonin and melatonin synthesis in peripheral blood mononuclear cells: Stimulation by interferon-gamma as part of an immunomodulatory pathway. J Interferon Res 8 (1988) 705-716
72. Fargin A., Raymond J.R., Lohse M.J., Kobilka B.K., Caron M.G., and Lefkowitz R.J. The genomic clone G-21 which resembles a beta-adrenergic receptor sequence encodes the 5-HT1A receptor. Nature 335 (1988) 358-360
73. Aune T.M., McGrath K.M., Sarr T., Bombara M.P., and Kelley K.A. Expression of 5HT1a receptors on activated human T cells. Regulation of cyclic AMP levels and T cell proliferation by 5-hydroxytryptamine. J Immunol 151 (1993) 1175-1183
74. Rabkin J.G., Wagner G.J., and Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: A randomized, placebo-controlled trial. Am J Psychiatry 156 (1999) 101-107
75. Zisook S., Peterkin J., Goggin K.J., Sledge P., Atkinson J.H., and Grant I. Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group. J Clin Psychiatry 59 (1998) 217-224
76. Rabkin J.G., Rabkin R., and Wagner G. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. J Clin Psychiatry 55 (1994) 92-97
77. Elliott A.J., Uldall K.K., Bergam K., Russo J., Claypoole K., and Roy-Byrne P.P. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry 155 (1998) 367-372
78. Kook A.I., Mizruchin A., Odnopozov N., Gershon H., and Segev Y. Depression and immunity: The biochemical interrelationship between the central nervous system and the immune system. Biol Psychiatry 37 (1995) 817-819
79. Lai J.P., Ho W.Z., Zhan G.X., Yi Y., Collman R.G., and Douglas S.D. Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes. Proc Natl Acad Sci U S A 98 (2001) 3970-3975
80. Ho W.Z., Lai J.P., Li Y., and Douglas S.D. HIV enhances substance P expression in human immune cells. FASEB J 16 (2002) 616-618
81. Scharton T.M., and Scott P. Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med 178 (1993) 567-577
82. Orange J.S., Wang B., Terhorst C., and Biron C.A. Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration. J Exp Med 182 (1995) 1045-1056
83. Mavilio D., Benjamin J., Daucher M., Lombardo G., Kottilil S., Planta M.A., et al. Natural killer cells in HIV-1 infection: Dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates [erratum Proc Natl Acad Sci U S A 2004 101:6326]. Proc Natl Acad Sci U S A 100 (2003) 15011-15016
84. Kottilil S., Shin K., Planta M., McLaughlin M., Hallahan C.W., Ghany M., et al. Expression of chemokine and inhibitory receptors on natural killer cells: Effect of immune activation and HIV viremia. J Infect Dis 189 (2004) 1193-1198
85. Mavilio D., Lombardo G., Benjamin J., Kim D., Follman D., Marcenaro E., et al. Characterization of CD56-/CD16+ natural killer (NK) cells: A highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A 102 (2005) 2886-2891
86. Leserman J., Jackson E.D., Petitto J.M., Golden R.N., Silva S.G., Perkins D.O., et al. Progression to AIDS: The effects of stress, depressive symptoms, and social support. Psychosom Med 61 (1999) 397-406
87. Leserman J., Petitto J.M., Golden R.N., Gaynes B.N., Gu H., Perkins D.O., et al. Impact of stressful life events, depression, social support, coping, and cortisol on progression to AIDS [see comment]. Am J Psychiatry 157 (2000) 1221-1228
88. Leserman J., Petitto J.M., Gu H., Gaynes B.N., Barroso J., Golden R.N., et al. Progression to AIDS, a clinical AIDS condition and mortality: Psychosocial and physiological predictors. Psychol Med 32 (2002) 1059-1073